NEW YORK, NY / ACCESSWIRE / August 24, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
James River Group Holdings, Ltd. (NASDAQ:JRVR)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/james-river-group-holdings-ltd-loss-submission-form?prid=18869&wire=1
Lead Plaintiff Deadline: September 7, 2021
Class Period: August 1, 2019 - May 5, 2021
Allegations against JRVR include that: (1) James River had not adequately reserved for its Uber policies; (2) James River was using an incorrect methodology for setting reserves that materially understated the Company's true exposure to Uber claims; (3) as a result, James River was forced to increase its unfavorable reserves in subsequent quarters even after cancelling the Uber policies; and (4) as a result of the foregoing, Defendants' statements about James River's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
Oatly Group AB (NASDAQ:OTLY)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/oatly-group-ab-loss-submission-form?prid=18869&wire=1
Lead Plaintiff Deadline: September 24, 2021
Class Period: May 20, 2021 - July 15, 2021
Allegations against OTLY include that: (a) Oatly overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; (b) the Company overstated its sustainability practices and impact; (c) the Company exaggerated its growth in China; and (c) as a result of the foregoing, Oatly's statements about its operations, business, and prospects were misleading during the Class Period.
Ardelyx, Inc. (NASDAQ: ARDX)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ardelyx-inc-loss-submission-form?prid=18869&wire=1
Lead Plaintiff Deadline: September 28, 2021
Class Period: August 6, 2020 - July 19, 2021
Allegations against ARDX include that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong